0000-0001-6138-6435 Employment
Employment history is unavailable.
Education
Education history is unavailable.
Projects & Funding
Projects & funding information is unavailable.
Publications (15)
- Optimizing the Cardiotoxicity Profile of Osimertinib via Scaffold Hopping: An Integrated Cheminformatics and Molecular Modeling Approach Save
- Flavokawain A: A Natural MAO-A Inhibitor With Therapeutic Promise for Depression Save
- Quantitative Analysis of Flavokawain a by Derivative and Area Under Curve UV-Spectrophotometry Save
- Lazertinib: A Cardio‐Safer Alternative to Osimertinib for Epidermal Growth Factor Receptor L858R/T790M Double‐Mutant Tyrosine Kinase Resistant Non‐Small Cell Lung Cancer Save
- Catalytic Lysine745 targeting strategy in fourth-generation EGFR tyrosine kinase inhibitors to address C797S mutation resistance Save
- Green analytical method development and validation for Flavokawain A using RP-HPLC in bulk and in-house tablet dosage forms,Développement et validation d’une méthode analytique verte pour le Flavokawaïne A par RP-HPLC dans les formes posologiques en vrac… Save
- HPTLC method for simultaneous determination of rivaroxaban and its aminomethyl process impurity/metabolite Save
- Integrated Computational Approach for Designing Potent EGFR-TK Inhibitors: QSAR, Docking, ADMET, and Molecular Dynamics Studies Save
- Optimizing Linezolid: Transforming It into a Selective MAO-B Inhibitor via a Toxicity-to-Activity Optimization Approach Save
- Prevalence of osimertinib-induced cardiotoxicity in non-small cell lung cancer patients: a systematic review and meta-analysis Save